$6.47
0.00%
Nasdaq, Fri, Dec 27 2024
ISIN
AGP8696W1045
Symbol
SVA
Sector
Industry

Sinovac Biotech Ltd. Stock price

$6.47
+0.00 0.00% 1M
+0.00 0.00% 6M
+0.00 0.00% YTD
+0.00 0.00% 1Y
+0.00 0.00% 3Y
+0.00 0.00% 5Y
+1.34 26.12% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.00 0.00%
ISIN
AGP8696W1045
Symbol
SVA
Sector
Industry

Key metrics

Market capitalization $464.94m
Enterprise Value $-6.93b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 17.26
EV/Sales (TTM) EV/Sales -16.15
P/S ratio (TTM) P/S ratio 1.08
P/B ratio (TTM) P/B ratio 0.07
Revenue growth (TTM) Revenue growth 1.98%
Revenue (TTM) Revenue $429.20m
EBIT (operating result TTM) EBIT $-392.28m
Free Cash Flow (TTM) Free Cash Flow $-401.60m
EPS (TTM) EPS $-1.31
Short interest 0.26%
Show more

Is Sinovac Biotech Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Sinovac Biotech Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Sinovac Biotech Ltd.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Sinovac Biotech Ltd.:

Buy
100%

Financial data from Sinovac Biotech Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
429 429
2% 2%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 218 218
71% 71%
51%
- Research and Development Expense 337 337
17% 17%
79%
-262 -262
81% 81%
-61%
- Depreciation and Amortization 130 130
20% 20%
30%
EBIT (Operating Income) EBIT -392 -392
74% 74%
-91%
Net Profit -125 -125
65% 65%
-29%

In millions USD.

Don't miss a Thing! We will send you all news about Sinovac Biotech Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sinovac Biotech Ltd. Stock News

Neutral
Business Wire
13 days ago
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today kicked off the enrollment for a Phase III clinical trial on a vaccine candidate to prevent HFMD caused by both Enterovirus 71 (EV71) and Coxsackievirus 16 (CA16). Notably, no multivalent vaccines against HFMD have yet been approved for marke...

Company Profile

Sinovac Biotech Ltd. is a holding company, which engages in the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. Its product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1 pandemic influenza, H1N1 influenza, and mumps. The company was founded in 1993 and is headquartered in Beijing, China.

Head office Antigua and Barbuda
CEO Wei Yin
Employees 3,037
Founded 1993
Website www.sinovac.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today